Menu
Menu
Most frequently asked questions and answers
NervGen trades in Canada on the TSX.V under the symbol NGEN and in the U.S. on the OTCQX under the symbol NGENF.
Refer to NervGen’s latest filed financial statements for the latest available share information.
NervGen’s fiscal year end is December 31st.
NervGen’s transfer agent is:
Computershare Investor Services Inc.
510 Burrard Street, 3rd Floor
Vancouver, BC V6C 3B9
T: (604) 661-9400
NervGen’s auditor is:
KPMG LLP
Pacific Centre
777 Dunsmuir Street, P.O. Box 10426
Vancouver, BC V7Y 1K3
CUSIP #: 64082X203
ISIN #: CA64082X2032
NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. The company’s lead target indication is spinal cord injury.
Contact
2955 Virtual Way
Suite 480
Vancouver, BC V5M 4X6
Phone: (778) 731-1711
Email: info@nervgen.com